Rituximab maintenance therapy: A step forward in follicular lymphoma

Haematologica

Volumn 92, Issue 6, 2007, Pages 826-833

  Van Oers, Marinus H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Follicular lymphoma; Maintenance therapy; Rituximab

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; INTERFERON; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE INTERVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INFECTION; INTERMETHOD COMPARISON; LONG TERM EXPOSURE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETREATMENT; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DISEASE MANAGEMENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE MANAGEMENT; HUMANS; LYMPHOMA, FOLLICULAR; TREATMENT OUTCOME;

EID: 34347252300     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10894     Document Type: Review

References (38)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18.
2. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-7.
3. Yuen AR, Kamel OW, Halpern J, Homing S. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995; 13:1726-33.
4. Ezdinli EZ, Harrington DP, Kucuk O, Silverstein MW, Anderson J, O'Connell MJ. The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer 1987; 60:156-60.
5. Steward WP, Crowther D, McWilliam LJ, Jones JM, Deakin DP, Todd ID, et al. Maintenance chlorambucil after CVP in the management of advanced-stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 1988;61:441-7.
6. Aviles A, Duque G, Talavera A, Guzman R. Interferon α2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996;20:495-9.
7. Arranz R, Garcia-Alfonso P, Sobrino P, Zamora P, Carrion R, Garcia-Larana J, et al. Role of interferon α2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 1998; 16:1538-46.
8. Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, et al. Interferon α consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin"s lymphoma: results of the Southwest Oncology Group randomized Phase III study 8809. J Clin Oncol 2000; 18:2010-6.
9. Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, et al. Maintenance of remission with human recombinant interferon α-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16:41-7.
10. Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001;85:29-35.
11. Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-23.
12. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33.
13. Schmitz K, Brugger W, Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. Br J Haematol 1999;106:571-2.
14. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-5.
15. Ghielmini M, Schmitz S-FH, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significandy increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood 2004;103:4416-23.
16. Hainsworth JD, Litchy S, Burris HA III, Scullin DC, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7.
17. Hainsworth JD, Litchy S, Morrissey L, Yardley DA, Greco FA. Rituximab as first-line and maintenance therapy for indolent non-Hodgkin's lymphoma (NHL): long-term follow-up of a Minnie Pearl Cancer Research Network Phase II trial. Blood 2003; 102:411a-2a[Abstract].
18. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: a randomized Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-95.
19. Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR, et al. Results of E1496: a Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 2004; 22 Suppl:6502[abstract].
20. Hochster HS, Weller E, Gascoyne RD, Ryan TS, Habermann TM, Gordon LI, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 Phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 2005; 106: 106a [abstract].
21. van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood 2006; 108:3295-301.
22. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) significantly prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma-results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 2004;104:3064-71.
23. Dreyling MH, Forstpointner R, Ludwig W, Gramatzki M, Boeck H, Haenel M, et al. Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma; follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23 Suppl:6528[Abstract].
24. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-8.
25. Brugger W, Hirsch J, Grüneback F, Repp R, Brossart P, Vogel W, et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective multicenter Phase II study. Ann Oncol 2004;15:1691-8.
26. Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, et al. Rituximab given after high-dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half the patients with follicular non-Hodgkin's lymphoma: 36 months results of a multicenter open-label Phase II trial (M39012 trial). Blood 2004;104:214a [Abstract].
27. Woods AC, Buckstein R, Mangel J, Imrie K, Spaner D, Crump M, et al. High dose therapy/ASCT with rituximab for in vivo purging and post-ASCT consolidation in relapsed follicular lymphoma achieves prolonged clinical and molecular remissions. Blood 2004;104:262a[Abstract].
28. Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004;15 283-90.
29. Neumann F, Harnsen S, Martin S, Kronenwett R, Kondakei M, Aivado M, et al. Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2006;85:530-4.
30. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
31. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005;23:1096-102.
32. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.
33. Ghielmini M, Schmitz SF, Burki K, Pichert G, Betticher DC, Stupp R, Wernli M, Lohri A, Schmitter D, Bertoni F, Cerny T The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11 Suppl 1: 123-6.
34. Fogarty GB, Bayne M, Bedford P, Bond R, Kannourakis G. Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol (R Coll Radiol) 2006; 18:155-6.
35. Herold M, Pasold R, Srock S, Neser S, Niederweiser D, Neubauer A, et al. Rituximab plus mitoxantrone, chlorambucil, prednisolone (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma - results of a Phase III study (OSHO39). Ann Oncol 2005;16 Suppl 5:v51-v2[Abstract].
36. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced-stage follicular lymphomas as compared to CHOP alone. Results of a prospective randomised study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2005; 106:3725-32.
37. Marcus R, Imrie K, Belch A, Cunningham C, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23.
38. Salles G, Foussard C, Mounier N, Morschhauser F, Chantal D, Thierry L, et al. Rituximab added to ·IFN-CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomised trial in 359 patients. Blood 2004;104:49a-50a[Abstract].